BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
To confirm the safety of BIBF 1120 at a dose level up to 200 mg x 2/day (i.e., overseas
recommended Phase III dose for combination treatment) with standard therapy of docetaxel (60
mg/m2 and 75 mg/m2) in Japanese advanced non small cell lung cancer (NSCLC) patients with
stage IIIB/IV or recurrent after failure of first line chemotherapy and to determine the
recommended dose for the Phase II trial.